Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 vaccine has been approved by the U.S. FDA for individuals 65 years and older or those with underlying conditions at high risk.
The vaccine is protein-based, non-mRNA, and targets the JN.1 variant of SARS-CoV-2.
Novavax's partner Sanofi will facilitate access to the vaccine for eligible individuals in the upcoming season.
Vaccine Approval
Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 season.
Immunization Indication
Nuvaxovid is indicated for individuals 65 years and older or 12-64 years with high-risk conditions for severe COVID-19 outcomes.
Adverse Reactions
Common adverse reactions include injection site tenderness, pain, redness, headache, muscle pain, fatigue, and more.
Commercialization Partnership
Sanofi leads commercialization efforts for Nuvaxovid, while Novavax receives tiered royalties from vaccine sales.
- Nuvaxovid is designed to induce immunity against the JN.1 lineage strains of COVID-19, including prevalent variants such as NB.1.8.1 and LF.7.
- The vaccine's approval for at-risk populations provides a crucial tool in the ongoing fight against COVID-19, especially considering the predominant JN.1 strain globally.
The approval of Nuvaxovid™ marks a significant milestone in the battle against COVID-19, offering a protein-based alternative for high-risk individuals. With Sanofi's support and Novavax's innovative technology, the vaccine aims to contribute to public health efforts.